Coadministration was not associated with an increased risk of side effects ...

On The Colin Cowherd Podcast, Colin Cowherd is joined by John Middlekauff to discuss the latest headlines in college football ...

Moderna (MRNA) has surged 94% in 2026 so far, crushing Pfizer (PFE) at just +4% and beating Novavax (NVAX) at +41%, as Moderna's leadership restructuring has signaled a 2027-2028 product launch push.

The company's pending vaccine approvals could help the stock continue its rise.

NEW YORK, June 6 (Reuters) - Pfizer (PFE.N), opens new tab presented data on Saturday that showed a monthly dose of an experimental obesity drug it acquired through ‌its purchase of Metsera last year ...

In a 32-week extension of its phase 2b VESPER-1 study, patients with obesity or overweight who escalated from placebo to a 2.4 mg weekly dose of berobenatide achieved a non-placebo-adjusted weight ...

Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) announced clinical trial data to reaffirm the effectiveness and safety of their messenger RNA-based COVID shots on Tuesday after President Donald Trump ...

Investors deciding between Lexicon Pharmaceuticals(NASDAQ:LXRX) and Pfizer(NYSE:PFE) face a choice between an emerging high-growth biotech player and an established global pharmaceutical titan with ...

A journal editor decided to retract and remove a bad study by an antivaxxer named Neil Z. Miller. RFK Jr. publicly demanded ...

Pfizer Inc. is pulling back the curtain on its obesity ambitions, releasing new data on an experimental weight-loss shot and outlining a strategy to claw its way into a leadership position in the ...

As it prepares to launch up to three new products from 2027 through 2028, Moderna is adjusting its way of doing business. The company has hired Ester Banque as its chief commercial officer and has ...

Lexicon Pharmaceuticals operates as a contender among biotech stocks by utilizing gene science to develop treatments for chronic conditions. The company primarily focuses on its commercial product, ...